BCL2 and neuroblastoma: MLN8237 destabilizes N-MYC and synergizes with BCL2/BCLxL inhibitor (venetoclax or navitoclax) to kill MYCN-amplified tumor cells including neuroblastoma and rhabdomyosarcoma (124, 125).